|
|
|
|
Investigators Debate Use of BEACOPP Versus ABVD fo
In recent years, clinicians have debated the merits of two combination drug regimens for patients with advanced-stage Hodgkin's lymphoma-ABVD (doxorubicin, bleomycin, vincristine and dacarbazine) and BEACOPP (bleomycin, etoposide...
|
|
|
Investigators Debate Use of BEACOPP Versus AB
In recent years, clinicians have debated the merits of two combination drug regimens for patients with advanced-stage Hodgkin's lymphoma-ABVD (doxorubicin, bleomycin, vincristine and dacarbazine) and BEACOPP (bleomycin, etoposide...
|
|
|
[Lymphoma and Myeloma] Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20
This Article Google Scholar Accepted July 28, 2008 Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516The Southwest Oncology Group Steven H.Bernstein,* Joseph M.
|
|
|
CytRx Unveils Clinical Development Plan for Pipeline Assets
Editors/Health/Medical Writers LOS ANGELES--(BUSINESS WIRE)--December 3, 2008--CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates...
|
|
|
CytRx Unveils Clinical Development Plan for Pipeline Assets
- CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of...
|
|
|
CytRx Unveils Clinical Development Plan For Pipeline Assets
CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of...
|
|
|
CytRx Unveils Clinical Development Plan for Pipeline Assets
CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of...
|
|
|
CytRx Unveils Clinical Development Plan for Pipeline Assets
Names World-Renowned Cancer Drug Expert Dr.Joseph Rubinfeld as Chief Scientific Advisor LOS ANGELES--(BUSINESS WIRE)--Dec 3, 2008 - CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on...
|
|
|
Method for treating cancer patients undergoing chemotherapy
Title: United States Patent: 7,439,234 Inventors: Hirschman; Shalom Z.(Riverdale, NY) Assignee: Advanced Viral Research Corporation (Yonkers, NY) Appl. No.: 10/456,668 Filed: June 5, 2003 Web Seminars-- Pharm/Biotech/etc. A method for...
|
